(RTTNews) - Anika Therapeutics, Inc. (ANIK) posted a first quarter loss from continuing operations of $3.96 million compared to a loss of $1.96 million, a year ago. Loss from continuing operations per share was $0.28 compared to a loss of $0.13. Adjusted net loss per share was $0.06 compared to profit of $0.13. Adjusted EBITDA was $0.1 million, for the quarter.
First quarter revenue from continuing operations was $26.2 million, a 10% decrease compared to the same period in 2024.
The company now expects fiscal 2025 adjusted EBITDA between a decline of 3% and an increase of 3%. Previously, the company projected growth in a range of 8% to 10%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
